Therapeutic Response

ER positive, HER2-positive, and PR positive status confers therapeutic sensitivity to Neratinib in patients with Invasive Breast Carcinoma.

Statements

Source and description
Nerlynx (neratinib) [product monograph]. HC. Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.